Hong Kong Pharmaceuticals and Healthcare Report Q3 2017
BMI View: A both ageing and growing population is the key driver of growth in Hong Kong'spharmaceutical and healthcare sector. Population trends in Hong Kong display relatively low birth rateand longer life expectancy. It is envisaged that the launching of new drugs and the formation of newdomestic and international partnerships will drive growth in the country's healthcare and pharmaceuticalssector. Hong Kong remains a key manufacturer for healthcare equipment, as well as devices and suppliesfor high health-risk diseases and injuries. The private-public partnership through government subsidy -allowing civilians to access healthcare services in the private healthcare facilities - is one of the moststrategic healthcare reforms to be implemented by the country
Headline Expenditure Projections
Pharmaceuticals: HKD9.6bn (USD1.2bn) in 2016 to HKD10.3bn (USD1.3bn) in 2017; +7.1% in localcurrency and 7.2% US dollars terms. Forecast revised due to new data source.
Healthcare: HKD152.4bn (USD19.6bn) in 2016 to HKD163.7bn (USD21.1bn) in 2017; +7.4% in localcurrency and 7.4% in US dollars terms.